·SEC EDGARLow
Taylor Joseph Michael sold $278K of CBLL
Taylor Joseph Michael sold 10,200 shares of Ceribell, Inc. (CBLL) at $27.22 ($0.28M total) on 2026-11-09.
StockNASDAQ · US · USDHealthcare · Medical Devices
$CBLL
Ceribell, Inc.
Ceribell is a medical technology company headquartered in Sunnyvale, California, that develops point-of-care EEG products for hospitals caring for patients with serious neurological conditions in acute care settings. Its Ceribell System combines portable hardware, including single-patient-use Wearables and a rechargeable recorder, with a web-based portal and AI-powered algorithms for EEG capture, remote access, seizure detection, and continuous monitoring. Clarity supports seizure detection, including electrographic status epilepticus, and the system also includes an FDA-cleared delirium monitoring solution. Ceribell has received FDA clearances for pediatric and neonatal seizure detection; its LVO stroke detection solution is in development. Ceribell makes money from sales of disposable Wearables and monthly subscriptions charged to hospital customers for use of Clarity, recorders, and its portal. As of December 31, 2025, its system has been adopted by more than 600 hospitals. The company’s commercial focus is the United States, and it has received a CE Mark for the system in Europe.
AlphAI earnings readthird quarter 2026 · NOV 3Ceribell Reports Third Quarter 2026 Financial ResultsVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $CBLLvia TradingView
AI sentiment · 7d5 articles
- Bullish
- 4
- Neutral
- 1
- Bearish
- 0
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $409K 2 txs
Woo Raymond1× · $132K
10b5-1 share of filings50%
Top stories · $CBLLMore →
·tradingview.com
Canaccord Genuity maintains CeriBell at Buy, raises price target to $33 from $26
Canaccord Genuity reaffirmed its Buy rating for CeriBell and increased its price target to $33 from $26, representing a 20.5% upside from the last close at $27.39.
·tradingview.com
CeriBell, Inc. Stock 12‑Month Price Target Raised to $31.57, Implies 12% Upside
CeriBell, Inc.'s average stock price target increased from $29.57 to $31.57, according to 7 analysts, with a potential 12% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' across 8 analysts.
CBLL sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CBLL (Ceribell, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent CBLL coverage spans financial news, earnings and regulation.
In the last 30 days, CBLL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($409K). The most active reporter was Woo Raymond, Chief Technology Officer, with 1 filing. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving CBLL
The insider sale may signal limited confidence and could weigh on the stock briefly.
Canaccord Genuity reaffirmed its Buy rating for CeriBell and increased its price target to $33 from $26, representing a 20.5% upside from the last close at $27.39.
CeriBell, Inc.'s average stock price target increased from $29.57 to $31.57, according to 7 analysts, with a potential 12% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' across 8 analysts.
Mix of strong top-line and utilization momentum versus widening losses and only modest guidance lift, with added uncertainty from potential $2.9M deferred legal fees.
Ceribell issued guidance that raises revenue expectations for 2026.
AlphAI scores every news story that mentions CBLL with an AI model for sentiment and relevance, and aggregates insider trades from Ceribell, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CBLL
Score
Taylor Joseph Michael sold $278K of CBLL
Taylor Joseph Michael sold 10,200 shares of Ceribell, Inc. (CBLL) at $27.22 ($0.28M total) on 2026-11-09.
Canaccord Genuity maintains CeriBell at Buy, raises price target to $33 from $26
Canaccord Genuity reaffirmed its Buy rating for CeriBell and increased its price target to $33 from $26, representing a 20.5% upside from the last close at $27.39.
CeriBell, Inc. Stock 12‑Month Price Target Raised to $31.57, Implies 12% Upside
CeriBell, Inc.'s average stock price target increased from $29.57 to $31.57, according to 7 analysts, with a potential 12% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' across 8 analysts.
CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions
CeriBell Inc (CBLL) reported Q3 2026 revenue of $29.3M, up 30% YoY, with 35 new hospitals added. Gross margin improved to 90%, but net loss widened to $21.4M. Full-year guidance raised to $115-$117M. Delirium monitoring pilot showed clinical impact, but no material revenue contribution yet. Operating expenses rose 36% YoY. CEO Jane Chao and CFO Scott Blomberg discussed growth strategies and 2027 outlook.
Ceribell Reports Third Quarter 2026 Financial Results
Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Third Quarter 2026 Financial Results Sunnyvale, Calif. – November 3, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
CBLL Maintained by TD Cowen -- Price Target Raised to $33.00
TD Cowen maintained a 'Buy' rating on CeriBell (CBLL), raising its price target to $33.00 from $29.00. The company has a market cap of $922.23 million and a GF Score™ of 12/100, indicating financial challenges. Insider activity shows significant selling. CBLL is unprofitable with a P/S ratio of 7.31x, reflecting a premium valuation.
TD Cowen maintains Buy rating on CeriBell, $33 price target
TD Cowen kept a Buy rating on CeriBell with a $33 price target, implying a 39.8% upside from the Oct 1 close of $23.61. The firm cited strong growth potential due to improved sales force productivity and a large market opportunity in EEG devices, including new markets and indications.
TD Cowen raises Ceribell stock price target on progress since IPO
TD Cowen raised its price target for Ceribell (CBLL) to $33 from $29, citing strong revenue growth and expanded market opportunities. The company reported $28.1M in Q2 revenue, up 33% YoY, and has beaten sales forecasts since its IPO. Multiple analysts have raised their price targets for Ceribell, reflecting positive sentiment and expectations for continued growth.
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
Ceribell, Inc. (Nasdaq: CBLL) received FDA 510(k) clearance for new software for its EEG system, enabling easier interpretation of brain activity trends. The update includes Alpha-Delta Ratio, Burst Suppression, and Amplitude-Integrated EEG monitoring, applicable to patients of all ages. The company expects to roll out the features in the first half of 2027.